==== Front PLoS Negl Trop Dis PLoS Negl Trop Dis plos PLOS Neglected Tropical Diseases 1935-2727 1935-2735 Public Library of Science San Francisco, CA USA 37339123 10.1371/journal.pntd.0011430 PNTD-D-23-00393 Research Article Biology and Life Sciences Organisms Eukaryota Animals Invertebrates Nematoda Loa Loa Biology and Life Sciences Zoology Animals Invertebrates Nematoda Loa Loa Biology and Life Sciences Neuroscience Cognitive Science Cognitive Neuroscience Cognitive Neurology Cognitive Impairment Biology and Life Sciences Neuroscience Cognitive Neuroscience Cognitive Neurology Cognitive Impairment Medicine and Health Sciences Neurology Cognitive Neurology Cognitive Impairment Medicine and Health Sciences Medical Conditions Tropical Diseases Neglected Tropical Diseases Loiasis Medicine and Health Sciences Medical Conditions Parasitic Diseases Nematode Infections Loiasis Biology and Life Sciences Neuroscience Cognitive Science Cognitive Neuroscience Cognitive Neurology Biology and Life Sciences Neuroscience Cognitive Neuroscience Cognitive Neurology Medicine and Health Sciences Neurology Cognitive Neurology Medicine and Health Sciences Mental Health and Psychiatry Dementia Medicine and Health Sciences Neurology Dementia Medicine and Health Sciences Vascular Medicine Atheromas Medicine and Health Sciences Health Care Health Statistics Morbidity Biology and Life Sciences Anatomy Body Fluids Blood Medicine and Health Sciences Anatomy Body Fluids Blood Biology and Life Sciences Physiology Body Fluids Blood Association between altered cognition and Loa loa microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of Congo Loiasis and neurocognition Checkouri Thomas Conceptualization Investigation Methodology Writing – original draft 1 Missamou François Investigation Supervision Writing – review & editing 2 Pion Sebastien D. S. Writing – review & editing 3 Bikita Paul Investigation Writing – review & editing 2 Hemilembolo Marlhand C. Investigation Writing – review & editing 2 3 Boussinesq Michel Writing – review & editing 3 Chesnais Cédric B. Data curation Formal analysis Funding acquisition Investigation Methodology Writing – review & editing 3 https://orcid.org/0000-0002-4400-5204 Campillo Jérémy T. Conceptualization Investigation Methodology Project administration Resources Supervision Validation Visualization Writing – review & editing 3 * 1 AP-HP, Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France 2 Programme National de Lutte contre l’Onchocercose, Direction de l’Épidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo 3 UMI 233 TransVIHMI, Université Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France Zunt Joseph Raymond Editor University of Washington, UNITED STATES The authors have declared that no competing interests exist. * E-mail: jeremy.campillo@ird.fr 20 6 2023 6 2023 17 6 e001143029 3 2023 3 6 2023 © 2023 Checkouri et al 2023 Checkouri et al https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Individuals with high Loa loa microfilarial densities are at risk of developing severe encephalopathy after administration of antiparasitic drugs. Apart from this finding, loiasis is considered benign with no effect on brain function. However, recent epidemiological data suggest an increased mortality and morbidity in L. loa infected individuals, underscoring the importance of studies on the possible neurological morbidity associated with loiasis. Methodology Using MoCA tests and neurological ultrasounds, we conducted a cross-sectional study to assess cognitive alteration in a population living in a rural area endemic for loiasis in the Republic of Congo. Fifty individuals with high microfilarial densities (MFD) were matched on sex, age and residency with 50 individuals with low MFD and 50 amicrofilaremic subjects. Analyses focused on individuals with MoCA scores indicating an altered cognition (i.e. < 23/30) and on the total MoCA score according to Loa loa MFD, sociodemographic characteristics and neurological ultrasound results. Principal findings MoCA scores were very low in the studied population (mean of 15.6/30). Individuals with more than 15,000 microfilariae per milliliter of blood (mean predicted score:14.0/30) are more than twenty times more likely to have an altered cognition, compared to individuals with no microfilaremia (mean predicted score: 16.3/30). Years of schooling were strongly associated with better MoCA results. Extracranial and intracranial atheroma were not associated with L. loa MFD. Conclusion/significance Loaisis microfilaremia is probably involved in cognitive impairment, especially when the MFD are high. These results highlight the urgent need to better understand loaisis-induced morbidity. Further studies investigating neurological morbidity of loiasis are needed. Author summary Individuals with high Loa loa blood microfilarial densities are at risk of developing a serious encephalopathy after administration of antiparasitic drugs. Apart from this major inconvenience, L. loa filariasis (loiasis) is considered a benign disease, with no effect on brain function. However, recent epidemiological data suggest an increased mortality and morbidity in L. loa infected individuals, underscoring the importance of studies on the possible neurological morbidity associated with loiasis. This cross-sectional study assessed cognition using MoCA tests (Montreal Cognitive assessments, a tool for early detection of mild cognitive impairment) and neurological ultrasound among 143 matched individuals with either no microfilaremia, low microfilaremia or high microfilaremia. People with high microfilaremia were more than twenty times more likely to have an altered cognition, compared to individuals with no microfilaremia. http://dx.doi.org/10.13039/100019180 HORIZON EUROPE European Research Council 949963 Chesnais Cédric B. This study was fully supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 949963, grant recipient: CBC). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. PLOS Publication Stagevor-update-to-uncorrected-proof Publication Update2023-06-30 Data AvailabilityThe authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting information file. Data Availability The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting information file. ==== Body pmcIntroduction Loiasis is a parasitic disease caused by the filarial nematode Loa loa. It is transmitted from human to human by tabanids (Chrysops spp.), mainly in forested areas of Central Africa. Female worms can produce millions of larvae (“microfilariae”, mf) that circulate in the bloodstream with a characteristic diurnal periodicity. The most frequent manifestations of loiasis are episodes of pruritus, sub-conjunctival migrations of the adult worms (“African eyeworm”), and transient angioedema (“Calabar swellings”). It is estimated that more than 15 million people are infected with L. loa in the world [1]. As of 2023, the disease is still considered benign: it is not included in the World Health Organization’s list of Neglected Tropical Diseases, and thus does not benefit from control campaigns. This dogma has been recently questioned [2] after specifically designed population studies found an increased mortality in L. loa-infected individuals [3]. Neurological attention has been drawn towards loiasis since cases of acute, fatal, encephalopathies were reported in infected individuals after treatment with ivermectin, hampering mass treatment for onchocerciasis (“river blindness”) in loiasis coendemic areas [4]. The main risk factor for Ivermectin-associated encephalopathy (IAE) is to have high levels of L. loa microfilaremia (> 30,000 mf per milliliter of blood [mf/mL]). The causative mechanism of IAE is not fully known, but pathological findings are consistent with a rupture of the brain-blood barrier (mf found in the cerebrospinal fluid) and hemorrhages due to an accumulation of mf in the brain microcirculation [5]. Besides this acute drug-related adverse event, various case reports have associated untreated loiasis with neurological disorders: spontaneous encephalopathies, severe headaches refractory to medical treatment, or nerve palsies [6]. Despite these alarming data about potential neurological consequences of loiasis, no epidemiological studies have ever been conducted to evaluate the brain function of L. loa-infected patients. The Montreal Cognitive Assessment (MoCA) score is a widely used screening tool for mild cognitive impairment (MCI) and dementia, addressing numerous cognitive domains [7]. The score ranges from 0 to 30, with higher scores indicating better cognition. The diagnosis of MCI requires evidence of impairment in at least one of those cognitive domains, including executive function, attention, memory, language or visuospatial skills, associated with cognitive complaint from the patient or observant [8]. There are many other recommended neuropsychological tests to confirm alteration of cognition, such as Mini-cog or Dementia severity rating scale (DSRS) [9]. The diagnosis of dementia is done when the cognitive impairment is sufficient to interfere with the complex activities of daily living [10]. Unlike other screening tools, MoCA score has been translated and used in multiple African countries, including in low-resource settings [11], and with illiterate patients [12]. Initially developed for neurodegenerative diseases such as Alzheimer’s in high income resources settings, it also has been used to screen for MCI and dementia in infectious (HIV-associated neurocognitive disorders) [13], genetic (Huntington’s disease) [14], or vascular (post-stroke dementia) [15] diseases. The original cut–off score of 26/30 was validated in high-income countries with wide access to education, but a 2017 meta-analysis suggested a better classification accuracy with a lower cut-off at 23/30, especially in more culturally and educationally heterogenous settings [16]. To address cognitive alteration in specific populations with no available normative values, the use of MoCA as a continuous score with regression-based corrections accounting for confounding factors has also been suggested [17,18]. Other highly prevalent infectious diseases in sub-Saharan Africa have been associated with MCI and progression to dementia, such as cerebral malaria [19] and onchocerciasis [20]. Similar to high-income countries, cerebrovascular diseases with large artery atheroma and cerebral microangiopathy are major contributors to the burden of dementia [21,22]. Strict adjustment for these confounding factors has been limited due to the lack of neurological specialists and access to brain magnetic resonance imaging (MRI) in rural areas [23]. Addressing the growing concerns about the understated neurological morbidity in loiasis, this study aims to assess whether cognitive alteration can be associated with L. loa infection, and its relation with L. loa microfilarial density levels. Methods Ethics statement This study has been approved by the Ethics Committee of the Congolese Foundation for Medical Research (N° 036/CIE/FCRM/2022) and by the Congolese Ministry of Health and Population (N° 376/MSP/CAB/UCPP-21). All participants received clear and appropriate information and signed an informed consent form for this specific study. Study area and population The MorLo (Morbidity due to Loiasis) project is an international collaborative study to assess the prevalence and incidence of Loa-related organ-specific complications in rural sub-Saharan Africa where loiasis is endemic and hypoendemic for onchocerciasis. In 2022, a cohort including 991 individuals living in 21 villages located in a radius of 50 kilometers around Sibiti, the capital town of the Lékoumou district of the Republic of Congo, was initiated. This region was selected because no mass drug administration with ivermectin for onchocerciasis or lymphatic filariasis had ever been implemented. To investigate neurological morbidity, we conducted this pilot cross-sectional study nested in the cohort study. Three groups were constituted within the whole cohort, to ensure adequate comparability. Each individual with high L. loa microfilarial density (MFD) (> 8000 mf/mL) was matched on sex, age (± 5 years) and village of residence with two others: one subject with low L. loa MFD (500 to 7999 mf/mL) and one amicrofilaremic individual. Patient and public involvement statement This study is nested in the cohort set up within the Sibiti hospital as part of the MorLo project. The project protocol was developed in collaboration with community health workers in the villages involved. Nurses from the Sibiti hospital administered the neurocognition tests after training by a neurologist. Community health workers acted as communicators within the involved villages to encourage people to visit health facilities when they had infectious symptoms as part of the MorLo cohort. The main results of the study were provided to community health workers in the involved villages. For each patient, the results of their tests were safely and confidentially kept at the health facility of their village and were accessible upon request. Laboratory procedures In May 2022, 50 μL of blood was collected by finger prick from each participant and spread on a microscope slide to prepare thick blood smear (TBS) between 10 am and 4 pm to account for the L. loa microfilaremia diurnal periodicity. The slides were dried at ambient temperature, dehemoglobinized and stained with Giemsa within 4 hours. All TBS were examined under a microscope at 100× magnification by experimented technicians to count the L. loa mfs and Mansonella perstans (another filariasis) mfs. Each TBS was read twice and the arithmetic mean of the counts was used for the statistical analysis. Finally, from blood collected in a heparinized tube, a L. loa Antibody Rapid Test (Loa ART, Drugs & Diagnostics for Tropical Diseases, San Diego, California) and an Ov16 Rapid Diagnostic Test (Ov16 RDT; Drugs & Diagnostics for Tropical Diseases, San Diego, California) were performed for each patient and read with a HRDR-200 smartphone-based chromatographic reader, as recommended by the manufacturer. Two skin snips were collected from each patient with positive Ov16 RDT using a Holth-type corneoscleral punch and incubated in saline at room temperature for 24 hours. Emerged microfilariae (mf) were counted using a microscope, and the individuals’ microfilarial density (MFD), expressed as mf per snip, were calculated using the arithmetic mean of the two snips. MoCA testing As a preparatory phase to the study, two local nurses were trained to MoCA testing, under the supervision of a neurologist, with healthy subjects. Then, during the study, the two nurses conducted the MoCA testing in a quiet individual room, after explaining the purpose of the test. Nurses were blinded to the parasitological results. Patients could answer the questions in French, Lingala or Kikongo (local languages), at their convenience. The number of years of education was self-reported. For the denomination task, we selected the lion, the crocodile and the snake from the 3 validated versions. Seven sub-scores were calculated: executive function (alternating trail making and verbal fluency), visuospatial abilities (figure copy and clock drawing), attention, concentration and working memory (digit span, sustained attention and serial subtraction), language (animal naming and sentence repetition), abstract reasoning (word and concept association), orientation (giving the calendar date and the location) and memory (restituting the list of 5 words given in French, Lingala or Kikongo as asked by the patient). Patients with MoCA scores lower than 23/30 were considered to present an altered cognition (AC). All MoCA results were rechecked by a neurologist (TC) blinded to the parasitological results. Neurological ultrasounds To examine a potential confounding factor for MCI, all patients had a cervical and transcranial Doppler and ultrasound examination with a CX–50 echograph (Phillips) and the appropriate probes. Cervical atheroma was defined as an intima-media thickness > 1.5 mm or presence of a plaque (focal structure encroaching at least 0.5 mm in the lumen) according to the Mannheim consensus [24]. We also measured blood velocities to characterize the degree of cervical stenosis, using the NASCET criteria [25]. Transcranial Doppler examination was done via the temporal and suboccipital bone windows, and we measured maximal systolic velocities (MSV), end diastolic velocities (EDV) and mean velocities (MV) from the middle cerebral artery (MCA). The pulsatility index (PI) was calculated automatically by the equation [(MSV-EDV)/MV]. Intracranial large artery atheroma was defined as blood velocities > 220/155 cm/s for MCA and > 140/100 cm/s for the basilar artery (BA), as published [26]. Considering PI as a surrogate marker of possible cerebral small-vessel disease, we defined a PI value of > 1.1 as a marker of microangiopathy, adapted from published criteria [27]. The missing data regarding the variables issued from the PI are due to a lack of temporal bone window. All ultrasound examinations were performed blinded to the MoCA and parasitological results. Statistical analysis Variables of interest were: the presence of AC (MoCA score < 23/30) and the MoCA score (continuous variable). Explanatory variables of interest were: sex, age (categorized as following: 18–40, 41–50, 51–60 and > 60 years old), number of years of schooling (continuous variable), history of cerebral malaria, high blood pressure (defined by a systolic pressure higher than 140 mmHg and/or a diastolic pressure higher than 90 mmHg; yes/no), smoking status, presence of L. loa mf in the TBS (microfilaremic status), Loa ART result and L. loa MFD (as a continuous variable, and in balanced categories: 0, 1–1999, 2000–6999, 7000–14,999 and ≥ 15,000 mf/mL), Ov16 results, presence of large artery atheroma and markers of cerebral microangiopathy. Ultrasound examination and cognitive evaluation results of participants were described and compared according to microfilaremic status. Chi-2 test (with Yates correction if one of the expected counts was lower than 5) and Kruskal-Wallis rank test were performed for categorical and continuous variables, respectively. Bivariate and multivariable logistic regression models were used to assess the associations between MoCA results and explanatory variables. Probabilities to have an AC (MoCA score < 23) according to L. loa MFD were calculated from the multivariable saturated logistic regression model. Using Poisson regression, MoCA score was analyzed as a continuous score to address considerable variation compared to the normative MoCA values developed in high income countries. Indeed, the lack of previously published normative values in similar settings (rural population of Central Africa), the relatively small sample size and the non-normal distribution of MoCA scores did not allow the use of Z–scores derived from the group with no microfilaremia. An analysis of each sub-item was performed with the appropriate models for the variables to be explained (negative binomial, Poisson or ordinal regression) and presented in S1 Table. Finally, we performed sensitivity analyses using different cut-offs (< 20, 21 and 22/30) for the definition of AC (S2 Table). The data used for analysis and the STROBE checklist for cross-sectional studies are available in S1 Data and S1 Strobe Checklist, respectively. Results Of the 150 individuals invited to participate, 143 were included in the study (3 were absent because they went hunting, 1 was away from the village and 3 were excluded because of hearing or visual deficiency). Demographics, cognitive and ultrasound data of the 3 groups are shown in Table 1. Only 2 and 9 subjects had significant (> 50% stenosis) extracranial and intracranial atheroma, respectively. A total of 8 individuals had markers of cerebral microangiopathy. No difference was found according to microfilaremic status. A total of 26 subjects (18.2%), of whom 80.8% were females, had no temporal bone window. For these individuals, no PI value was measured and intracranial atheroma was assessed in the BA. 10.1371/journal.pntd.0011430.t001 Table 1 Neurological examination and MoCA results according to loiasis status. Characteristic Whole population Non-microfilaremic group Microfilaremic group All 500–7999 mf/mL ≥ 8000 mf/mL P * Number of patients (n, %) 143 47 (32.9%) 96 (67.1%) 47 47 Ultrasound examination  Extracranial atheroma   Carotid IMT [mm] .753    Mean ± SD 0.67 ± 0.18 0.66 ± 0.17 0.67 ± 0.19 0.69 ± 0.19 0.65 ± 0.19    Median [IQR] 0.63 [0.53–0.78] 0.61 [0.53–0.76] 0.64 [0.53–0.80] 0.69 [0.53–0.77] 0.60 [0.51–0.80]   Any ICA atheroma 20 (14.1%) 7 (14.9%) 13 (13.7%) 9 (19.1%) 4 (8.5%) .876   ICA atheroma > 50% 2 (1.4%) 1 (2.1%) 1 (1.1%) 1 (2.1%) 0 NC  Intracranial atheroma   MCA stenosis > 50% 9 (6.3%) 2 (4.3%) 7 (7.4%) 4 (8.5%) 3 (6.4%) .474   Markers of microangiopathy 8 (5.6%) 3 (6.4%) 5 (5.2%) 2 (4.3%) 3 (6.3%) .261 Cognitive evaluation  Total MoCA score .454   Mean ± SD 15.6 ± 5.8 16.2 ± 5.7 15.3 ± 5.9 15.5 ± 6.2 15.1 ± 5.7   Median [IQR] 16 [11–20] 16 [11–20] 15.5 [11–19] 15 [11–20] 15 [10–19]  Sub–scores (Mean ± SD)   Executive function (/2) 0.30 ± 0.57 0.42 ± 0.65 0.24 ± 0.52 0.32 ± 0.59 0.17 ± 0.43 .061   Visuospatial ability (/4) 1.38 ± 1.44 1.19 ± 1.36 1.48 ± 1.48 1.55 ± 1.50 1.38 ± 1.47 .299   Attention (/6) 2.33 ± 1.96 2.66 ± 1.92 2.18 ±1.97 2.51 ± 1.99 1.85 ± 1.94 .142   Language (/5) 3.82 ± 1.20 3.77 ± 1.22 3.84 ± 1.19 3.62 ± 1.41 4.04 ± 0.90 .714   Abstract reasoning (/2) 1.63 ± 0.63 1.68 ± 0.51 1.60 ± 0.69 1.47 ± 0.75 1.72 ± 0.61 .888   Memory (/5) 1.27 ± 1.77 1.47 ± 1.80 1.17 ± 1.76 1.38 ± 1.82 0.98 ± 1.69 .282   Orientation (/6) 4.91 ± 1.33 5.06 ± 1.17 4.83 ± 1.40 4.7 ± 1.56 4.98 ± 1.23 .430 Abbreviations: SD, Standard deviation; IQR, interquartile range; NC, not calculable; IMT, Intima media thickness; ICA, Internal carotid artery; MCA, Middle cerebral artery * represents the p-value associated with the Chi-2 or Kruskal-Wallis rank test (according to the variable) between the microfilaremic and non-microfilaremic groups. Only two individuals had mfs of M. perstans in their blood, both in low densities (60 and 600 mf/mL). Finally, only 8 individuals tested positive for Ov16. Of the 8, none had O. volvulus mfs in the skin. Characteristics of the study population according to the presence of an AC are presented in Table 2. Females were more represented in the cognitive alteration category (P = 0.014), and a higher number of years of education was strongly associated with no cognitive alteration (P < .001). In the population, arithmetic mean MoCA score was 15.6 (range: 3–28). The least successful parts were executive function (0.30/2) and memory (1.27/5) and the most successful ones were orientation (4.91/6) and abstract reasoning (1.63/2). Verbal fluency was below than 11 words in 91.6% of cases, with an average number of 4.3 words given. 10.1371/journal.pntd.0011430.t002 Table 2 Characteristics of the study population according to altered cognition status. Characteristic Whole population Altered Cognition* No Altered Cognition P Number of patients (n, %) 143 122 (85.3%) 21 (14.7%) Age in years (mean ± SD) 51.4 ± 13.9 51.9 ± 13.5 48.4 ± 15.9 .321 Sex-ratio (M/F) 2.0 1.7 9.5 .014 Hypertension (n, %) 40 (28.0%) 36 (29.5%) 4 (19.1%) .324 Tobacco use (n, %) 33 (23.1%) 28 (23.0%) 5 (23.8%) .931 Cerebral malaria history (n, %) 12 (8.4%) 1 (4.8%) 11 (9.0%) .516 Years of education (mean ± SD) 4.8 ± 3.9 4.0 ± 3.6 9.3 ± 2.3 < .001  No school education (n, %) 39 (27.3%) 39 (32.0%) 0  1–6 years education (n, %) 55 (38.5%) 52 (42.6%) 3 (14.3%)  > 6 years education (n, %) 49 (34.3%) 31 (25.4%) 18 (85.7%) Ov16 Rapid Diagnostic Test (n, %) .857  Positive 8 (5.6%) 7 (5.7%) 1 (4.8%)  Negative 135 (94.4%) 20 (95.2%) 115 (94.5%) Loa Antibody Rapid Test (n, %) .187  Positive 117 (86.0%) 98 (84.5%) 19 (95.0%)  Negative 19 (14.0%) 18 (15.5%) 1 (5.0%)  MD 7 6 1 Loa microfilaremic status (n, %) .291  Positive 96 (67.1%) 84 (68.9%) 12 (57.1%)  Negative 47 (32.9%) 38 (31.1%) 9 (42.9%) Loa MFD (mf/mL) .159  Mean ± SD 7783 ± 12 209 8482 ± 12 944 3723 ± 4943  Median [IQR] 2220 [0–12,240] 3145 [0–12,610] 1770 [0–4450] Loa MFD categories (n, %) .380  0 mf/mL 47 (32.9%) 38 (31.1%) 9 (42.9%)  1–4999 mf/mL 44 (30.8%) 37 (30.3%) 7 (33.3%)  5000–14 999 mf/mL 27 (18.9%) 23 (18.9%) 4 (19.0%)  ≥15 000 mf/mL 25 (17.5%) 24 (19.7%) 1 (4.8%) Abbreviations: SD, Standard deviation; MFD, microfilarial density; IQR, interquartile range. * defined if MoCA total score < 23 Results from the logistic regression model analyses explaining the presence of AC are presented in Table 3. Individuals with ≥ 15,000 mf/mL were 21.80 [95% CI: 1.25–380.15] times more likely to have an AC, compared to individuals with no microfilaremia (P = .043). Probabilities of having an AC, calculated from this saturated model, were estimated at 0.80 and 0.97 among individuals with 0 and ≥ 15,000 mf/mL, respectively. Predicted probabilities of having an AC (calculated according to the number of years of schooling and the MFD categories) highlighted a significantly higher risk of having an AC when the MFD is high (≥ 15,000 mf/mL), particularly for individuals with the highest education levels (Fig 1, panel A). Sensitivity analyses using different MoCA cut-offs were consistent with the main analysis results, with a significant (or borderline significant) association found with high Loa MFD levels for each cut-off (S2 Table). 10.1371/journal.pntd.0011430.g001 Fig 1 Prediction of altered cognition and total MoCA score as affected by years of schooling and Loa loa microfilarial densities. Panel A. Probabilities to have an altered cognition. Panel B. Total MoCA scores. 10.1371/journal.pntd.0011430.t003 Table 3 Results from the logistic regression models explaining altered cognition status. Variable cOR [95% CI] P aOR [95% CI] P Age (years old)  18–40 Ref. Ref.  41–50 1.81 [0.52, 6.35] .351 2.40 [0.34, 17.00] .380  51–60 2.07 [0.48, 8.93] .327 1.54 [0.15, 15.67] .715  > 60 1.56 [0.47, 5.16] .470 0.20 [0.02, 2.05] .174 Sex  Female Ref. Ref.  Male 0.18 [0.04, 0.81] .025 0.38 [0.04, 3.64] .401 History of cerebral malaria (ref. No) 1.98 [0.24, 16.21] .524 0.75 [0.03, 18.38] .860 High blood pressure (ref. No) 1.78 [0.56, 5.66] .329 0.83 [0.11, 6.05] .856 Use of smoking tobacco (ref. No) 0.95 [0.32, 2.83] .931 0.41 [0.06, 2.59] .342 Years of schooling (continuous) 0.62 [0.50, 0.76] < .001 0.53 [0.40, 0.70] < .001 L. loa MFD (mf/mL)  0 Ref. Ref.  1–1999 1.50 [0.36, 6.19] .575 3.00 [0.33, 27.37] .330  2000–6,999 1.24 [0.34, 4.53] .741 1.20 [0.15, 9.74] .859  7000–14,999 1.18 [0.32, 4.33] .798 1.55 [0.21, 11.19] .663  ≥ 15,000 5.68 [0.68, 47.75] .110 21.80 [1.09, 433.05] .043 Loiasis Rapid Antibody Test  No Ref. Ref.  Yes 0.29 [0.03, 2.28] .237 0.12 [0.01, 2.81] .189  MD 0.33 [0.02, 6.19] .461 0.14 [0.01, 11.95] .384 Presence of large artery atheroma (ref. No) 2.47 [0.54, 11.33] .243 3.14 [0.37, 26.56] .293 Possible cerebral microangiopathy  No Ref. Ref.  Yes 0.55 [0.10, 2.98] .492 0.08 [0.01, 1.73] .107  MD 2.22 [0.48, 10.27] .308 0.19 [0.02, 2.22] .188 Abbreviations: cOR, crude Odds-Ratio; aOR, adjusted Odds-Ratio; 95% CI, 95% confidence intervals; MD, Missing data Results from the Poisson regression explaining total MoCA score are presented in Table 4. Individuals with MFD ≥ 15,000 mf/mL had a mean predicted MoCA score of 14.0 compared to 16.3 for amicrofilaremic individuals. Years of schooling were highly associated with better MoCA scores with a mean predicted score of 11.1 for individuals who have not been to school, 15.2 for those who have been to school for 5 years and 20.9 for those who have been to school for 10 years. Predicted MoCA scores (calculated according to the number of years of schooling and the MFD categories) showed significantly lower scores in the higher MFD category, for any level of education (Fig 1, panel B). 10.1371/journal.pntd.0011430.t004 Table 4 Results from the Poisson regression models explaining MoCA total score. Variable cCoeff. [95% CI] P aCoeff. [95% CI] P Age (years old)  18–40 Ref. Ref.  41–50 -0.10 [-0.21, 0.01] .075 -0.10 [-0.22, 0.02] .095  51–60 -0.28 [-0.41, -0.15] < .001 -0.12 [-0.26, 0.02] .088  > 60 -0.37 [-0.48, -0.25] < .001 -0.12 [-0.26, 0.03] .119 Sex  Female Ref. Ref.  Male 0.34 [0.24, 0.43] < .001 0.10 [-0.02, 0.22] .121 History of cerebral malaria (ref. No) 0.01 [-0.14, 0.16] .862 0.06 [-0.10, 0.22] .454 High blood pressure (ref. No) -0.22 [-0.32, -0.12] < .001 0.01 [-0.10, 0.12] .870 Use of smoking tobacco (ref. No) 0.10 [0.00, 0.20] .041 0.05 [-0.06, 0.16] .350 Years of schooling (continuous) 0.07 [0.06, 0.08] < .001 0.06 [0.05, 0.07] < .001 L. loa MFD (mf/mL)  0 Ref. Ref.  1–1999 -0.01 [-0.14, 0.11] .840 -0.09 [-0.22, 0.04] .184  2000–6,999 -0.08 [-0.21, 0.04] .188 -0.03 [-0.16, 0.10] .618  7000–14,999 0.04 [-0.08, 0.16] .490 0.01 [-0.13, 0.13] .980  ≥ 15,000 -0.18 [-0.31, -0.05] .005 -0.16 [-0.29, -0.02] .022 Loiasis Rapid Antibody Test  No Ref. Ref.  Yes 0.13 [-0.01, 0.26] .052 0.03 [-0.10, 0.17] .563  MD 0.19 [-0.03, 0.41] .087 -0.01 [-0.25, 0.22] .898 Presence of large artery atheroma (ref. No) -0.22 [-0.33, -0.10] < .001 -0.08 [-0.21, 0.04] .182 Possible cerebral microangiopathy  No Ref. Ref.  Yes -0.27 [-0.47, -0.07] .008 -0.04 [-0.25, 0.16] .669  MD -0.26 [-0.38, -0.15] < .001 0.05 [-0.10, 0.20] .507 Abbreviations: cCoeff, crude ß coefficients; aCoeff, adjusted ß coefficients; 95% CI, 95% confidence intervals; MD, Missing data Mean MoCA total scores and each sub-item scores are presented by age, sex, Loa microfilaremic status, and MFD categories in S3 Table. High L. loa MFD was significantly associated with lower results in executive function (P = .028, trend test of Cuzick) and attention (P = .015, trend test of Cuzick) exercises. Results from models explaining each MoCA sub-items are presented in S1 Table. By comparison to amicrofilaremic subjects, individuals with ≥ 15,000 mf/mL were more likely to have poor results for memory (adjusted incidence rate ratio [aIRR] = 0.28; P = .014), attention (aIRR = 0.55; P = .003) and executive function (adjusted Odds Ratio = 0.16, P = 0.036) exercises. Discussion Using a cross-sectional design, we report an association between low MoCA scores and L. loa microfilaremia. To our knowledge, this is the first epidemiological study to report neurological morbidity associated with loiasis. We used MoCA testing, a screening tool for MCI and dementia mainly used in high-income countries and not validated for the specific population investigated. The majority of patients had a positive screening for cognitive impairment (defined by a MoCA score < 23), probably related to the fact that normative values of MoCA are different in this population of rural Congo. However, previous studies had shown high sensibility and specificity (83% and 88%, respectively) for dementia using the 23/30 cut-off [16]. MoCA testing has been successfully used in rural areas in Africa to detect confirmed infectious causes of dementia such as HIV-associated neurocognitive disorders, even if the authors noted the limitation of accuracy due to differences in socio-cultural context [28,29]. Although the significant association between AC and loiasis was observed in patients with high MFD, we observed no clear dose–effect of L. loa MFD on MoCA score. This may reflect a threshold effect at which the neurocognitive effect would appear, or a lack of power due to sample size. Further studies will help to better understand this phenomenon and to evaluate the validity of this MoCA in rural areas of Central Africa. Nevertheless, the approach using continuous MoCA scores with strict adjustment for confounding socio-demographic and pathological factors, as well as the difference found mainly in patients having attended school for more than 10 years (that limits a potential floor effect), strengthens the likelihood of our results. Overall, we demonstrate a specific alteration of cognition in individuals with L. loa microfilaremia. After screening with MoCA, a neuropsychological analysis of specifically altered cognitive domains is needed to confirm MCI. The MoCA sub-items of memory, attention, and executive function were selectively impacted by L. loa MFD in this study. All those subdomains of MoCA testing are recognized in international criteria as objective evidence to diagnose MCI, suggesting a genuine effect of L. loa MFD on cognition [9]. These results concerning MoCA sub-items should be interpreted with caution, as that they are strongly influenced by illiteracy status [12]. However, we adjusted for educational level and the sampled population was homogeneous (subjects lived in similar villages in terms of access to education and socio-demographic characteristics), strengthening the plausibility of the results. The further step to diagnose dementia in this population would be the assessment of alteration of the subjects’ autonomy in daily living. In the specific context of the Republic of Congo, the situation is particularly concerning with social stigma and absence of caregivers reported for patients suffering from dementia [30] The pathogenesis of neurocognitive dysfunction in the context of chronic microfilaremia is yet to discover. Knowledge about potential brain lesions due to L. loa mainly comes from cases of IAE. Patients present with a progressive comatose state with diffuse electroencephalographic slowing, acute proteinuria, and lumbar puncture revealing the presence of living mf in the cerebrospinal fluid [5]. An alteration of the retinal microcirculation, with “cotton wool exudates” and retinal hemorrhages were reported in cases of IAE, but also in untreated individuals with high L. loa MFD [31,32]. Disruption of the blood–brain barrier by dead microfilariae or proinflammatory cytokines has also been suggested as a mechanism in historical cases of spontaneous encephalopathies [33]. Emboli of dead mf in small cerebral vessels, surrounded by parenchymal granulomas were found during the autopsy of baboons experimentally infected with L. loa after treatment with ivermectin, but also in untreated animals [34]. In humans, perivascular granulomas were reported in a subject who died after having developed an IAE [35]. Interestingly, a high MFD is the main risk factor for IAE [4], and only individuals with high MFD had an alteration of cognition in this study. Considering a possible similarity between the mechanism of IAE and the alteration of cognition found in chronically infected individuals in our study, two main mechanisms are to be tested. A first possible mechanism is an impairment of cerebral microcirculation by the chronic circulation of mf. Cerebral microcirculation is also altered in cerebral small-vessel disease, which is a major cause of MCI and dementia in high income countries [36]. The use of PI as a surrogate marker for microangiopathy, as well as the proportion (18.2%) of patients without temporal bone window are major limitations on the interpretability of our results for this hypothesis. Other possible mechanisms are related to the presence of the parasite in the cerebrospinal fluid or in the subdural space [37–40], or disruption of the blood–brain barrier [33]. Even if lumbar puncture and brain imaging were not available, the absence of chronic headaches and visual impairment in our patients makes this mechanism unlikely. The relationships between L. loa MFD, cerebrovascular disease and cognitive impairment remain to be studied. Further investigation on the mechanism of cognitive alteration from loiasis would require brain MRI, which is not available in rural Congo, or lumbar puncture, an invasive procedure with no guaranteed benefit/risk ratio. Other infections may explain the altered cognition in this population such as onchocerciasis and intestinal worms (hookworm whipworm and roundworm). Indeed, uncontrolled seizures could result from epilepsy associated with onchocerciasis [41]. Those seizures could alter cognition, independently of L. loa infection. However, only 8 individuals in the study population had a positive rapid serological test for Ov16 and of these, none had mfs in the skin. Intestinal worms, particularly hookworms, have been described as being involved in impairments in intellectual and cognitive development in children [42–44]. These are common conditions in the study population, but there is no reason why individuals with L. loa microfilaremia should carry more intestinal worms than individuals without. It is therefore unlikely that the presence of intestinal worms is a confounding factor in our study. Our study has several limitations. The cross–sectional design is not sufficient to establish a causal relationship between L. loa infection and neurocognitive disease. The lack of normative values for the screening test used in our population, as well as the relatively small sample size clearly limits the interpretability of our results. These limitations are inherent to the “pilot-study” design aimed to identify potential neurological morbidity in a disease which is largely considered as benign. To address these limitations, larger studies with comprehensive and validated cognitive testing, long term follow–up, brain imaging and adjustment for coinfections are currently under planning. Overall, the alteration of global cognition and critical cognitive domains by L. loa microfilaremia in clinically meaningful proportions could place loiasis as a significant risk factor for dementia in Central Africa, especially for the young population. This could add to the growing socio-economic burden of dementia in rural Africa, with the lack of efficient diagnostic procedures and care systems for these patients. Our results provide the rationale for further studies investigating the impact of L. loa microfilaremia on cognitive function. This should push further the consideration that loiasis is not a benign disease. Supporting information S1 Table Sub-items models (binomial negative, Poisson or ordinal) with L. loa microfilarial densities in categories. (DOCX) Click here for additional data file. S2 Table Sensitivity analysis: Adjusted logistic regression explain using different MoCA score cut-offs for the definition of altered cognition. (DOCX) Click here for additional data file. S3 Table MoCA scores by age, sex, Loa microfilaremic status and L. loa MFD. (DOCX) Click here for additional data file. S1 Strobe Checklist STROBE Statement: Checklist of items that should be included in reports of cross-sectional studies. (DOCX) Click here for additional data file. S1 Data Anonymized data. (CSV) Click here for additional data file. We are grateful to local authorities for their help and support. We thank the individuals in the study for agreeing to participate. We thank the health personnel of the Sibiti hospital for their participation in the study. We thank community health workers of each village for their help and advices. We thank the drivers for their work. 10.1371/journal.pntd.0011430.r001 Decision Letter 0 Zunt Joseph Raymond Academic Editor Tamarozzi Francesca Section Editor © 2023 Zunt, Tamarozzi 2023 Zunt, Tamarozzi https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version0 15 May 2023 Dear Dr. Checkouri, Thank you very much for submitting your manuscript "Association between altered cognition and Loa loa microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of Congo" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments. Please pay special attention to the comments from: Reviewer #3 regarding the use of MoCA testing for screening for cognitive impairment and need for subsequent confirmatory testing; Reviewer #2: additional information would be welcome regarding how cohort studies would help you address the limitations of this exploratory cross-sectional study; and Reviewer #1 regarding how test results were shared (or will be planned to be shared) with the public health system and population. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation. When you are ready to resubmit, please upload the following: [1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. [2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file). Important additional instructions are given below your reviewer comments. Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts. Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments. Sincerely, Joseph Raymond Zunt Academic Editor PLOS Neglected Tropical Diseases Francesca Tamarozzi Section Editor PLOS Neglected Tropical Diseases *********************** Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The objectives are clearly articulated with clear testable hypothesis. The study design is appropriate to address the stated objectives, but not clear specified as historical cohort study. The population is clearly described and appropriate for the hypothesis being tested. The sample size was not clearly calculted, but this is the forst time such study is conducted. It would heve been difficult to calculate the sample size without at least some preliminary results. THe statistical analysis are appropriate There is no concerns about ethical or regulatory requirement. They are all met. Reviewer #2: Methodology: the objectives of the study are clearly articulated, the design is appropriate, given the study context, the population is well described, the sample size is sufficient, even though not justified, The statistical methods used are correct to support the conclusions. The study received ethical clearances from regulatory instances. Reviewer #3: 1. The MOCA is a screening test that may over estimate the frequency of cognitive impairment. This is more likely when the cut-off is not based on local norms of the study area. The study should have used the 50 individuals with MF to get their mean score and then generate z scores to identify those who scores fall below 2 standard deviations of the control group mean score. 2. The three groups are not well described in the methods. More details are needed. -------------------- Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: The results are clearly and completly presented. The tables are appropriate. Reviewer #2: The analyses presented match the analysis plan and the results are clearly and completely presented. Tables and figures are of good quality and clarity. Reviewer #3: 1. I find the frequency of impairment (>80%) too high to be true....and this is probably due how they determined impairment. A better method has been suggested above. 2. The results should be presented for the 3 different groups (high and low MF and the no MF group). How do the sociodemographic variables compared across the groups (Table 1) and MOCA scores (table 2). -------------------- Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: The conclusion are supported by the data presented. The limitation of the analysis are described but not complet. No recommendation was mad concerning further exploration in the domain despite the dougts concerning the results of the present study. Reviewer #2: The conclusions are supported by the data presented. the limitations of the analysis are described, but more description need to be added to what is presented. The public health relevence is clearly addressed Reviewer #3: 1. The discussion and conclusion should mention the limitations mentioned above (use of a screening test that may overestimate the impairment rates) 2. The authors in attempting to explain how MF lead to cognitive impairment could consider the BBB integrity being compromised by proinflammatory cytokines in response to infection. Future studies could consider investigating that. -------------------- Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: Data presentation modifications have been suggested above -------------------- Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: General comment The paper by Checkouri et al on the association between altered cognition and Loa loa microfilaremia: first evidence from a cross-sectional study in a rural area of the Republic of Congo is an important contribution of the impact of loiasis, the neglected among the neglected by the scientific community. It is the first time the neuropsychiatric complications are described particularly in subject harboring very high MFD. In the logistic regression models and the Poisson regression models, there is no dose effect for the relation between the high MFD and the altered cognition statute. This put some doubt on this relation and as this has never been demonstrated elsewhere adding to possible confonding factors, the authors should clearly recommend the conduct of similar studies in different settings to confirm or to refute this relationship between the high loa MFD and the altered cognition. Specific comment Page 6 Study data were provided to community health workers in the involved villages to inform the local community of the study results and patients of their test results. I will suggest The results of the study were shared with the local health personnel to explain to the community members, and the individual results of the patients where put at their disposal through the local health personnel. Page 8 The results of MoCA by a neurologist blinded to the parasitological results. It is not mentioned if the trained nurses examined the patients blinded of parasitological results. Reviewer #2: The authors of this manuscript present for the first time an association between high density of Loa loa microfilariae in the peripheric blood and the alteration of cognition in a population living in endemic area of loiasis, independent of antifilarial treatment. The findings from this pilote study constitute a breakthrough for this very neglected tropical disease (Loiasis) and deserve to be shared with scientific community working in this field of research. The authors should highlight the fact that the study design they used “Cross-sectional” is the weakest design to establish causal relationship between exposure and disease in etiologic epidemiology. The good thing is that this study is nested in the cohort set up in a more ambitious project “Morbidity due to Loiasis” and one can expect that the findings from the long term follow up of participants would validate the preliminary observations. Reviewer #3: The authors designed an exploratory study to examine the association between loa loa infection and cognitive functioning. Challenges observed are the use of a screening test and not using local norms to determine impairment which led to an unusually high rate of impairment. -------------------- PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Joseph Kamgno (MD, PhD) Reviewer #2: No Reviewer #3: No Figure Files: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Data Requirements: Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5. Reproducibility: To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 10.1371/journal.pntd.0011430.r002 Author response to Decision Letter 0 Submission Version1 1 Jun 2023 Attachment Submitted filename: Response_PLOSNTD_Final.docx Click here for additional data file. 10.1371/journal.pntd.0011430.r003 Decision Letter 1 Zunt Joseph Raymond Academic Editor Tamarozzi Francesca Section Editor © 2023 Zunt, Tamarozzi 2023 Zunt, Tamarozzi https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version1 3 Jun 2023 Dear Dr Campillo, We are pleased to inform you that your manuscript 'Association between altered cognition and Loa loa microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of Congo' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Joseph Raymond Zunt Academic Editor PLOS Neglected Tropical Diseases Francesca Tamarozzi Section Editor PLOS Neglected Tropical Diseases *********************************************************** Thank you for your thoughtful responses to the reviewers' comments. I do think it would be helpful to include the sensitivity analysis regarding MoCA score and L. loa MFD in the Supplementary material. 10.1371/journal.pntd.0011430.r004 Acceptance letter Zunt Joseph Raymond Academic Editor Tamarozzi Francesca Section Editor © 2023 Zunt, Tamarozzi 2023 Zunt, Tamarozzi https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 14 Jun 2023 Dear Dr Campillo, We are delighted to inform you that your manuscript, "Association between altered cognition and Loa loa microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of Congo," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases ==== Refs References 1 Zouré HGM , Wanji S , Noma M , Amazigo UV , Diggle PJ , Tekle AH , et al . The Geographic Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5 : e1210. doi: 10.1371/journal.pntd.0001210 21738809 2 Jacobsen KH , Andress BC , Bhagwat EA , Bryant CA , Chandrapu VR , Desmonts CG , et al . A call for loiasis to be added to the WHO list of neglected tropical diseases. Lancet Infect Dis. 2022;22 : e299–e302. doi: 10.1016/S1473-3099(22)00064-0 35500592 3 Chesnais CB , Takougang I , Paguélé M , Pion SD , Boussinesq M . Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17 : 108–116. doi: 10.1016/S1473-3099(16)30405-4 27777031 4 Gardon J , Gardon-Wendel N , Demanga-Ngangue , Kamgno J , Chippaux JP , Boussinesq M . Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350 : 18–22. doi: 10.1016/S0140-6736(96)11094-1 9217715 5 Boussinesq M , Gardon J , Gardon-Wendel N , Chippaux J-P . Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2 Suppl 1 : S4. doi: 10.1186/1475-2883-2-S1-S4 14975061 6 Buell KG , Whittaker C , Chesnais CB , Jewell PD , Pion SDS , Walker M , et al . Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations. Open Forum Infect Dis. 2019;6 : ofz417. doi: 10.1093/ofid/ofz417 31696139 7 Nasreddine ZS , Phillips NA , Bédirian V , Charbonneau S , Whitehead V , Collin I , et al . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53 : 695–9. doi: 10.1111/j.1532-5415.2005.53221.x 15817019 8 Albert MS , DeKosky ST , Dickson D , Dubois B , Feldman Howard H , Fox Nick C , et al . The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2011;7 : 270–279. doi: 10.1016/j.jalz.2011.03.008 21514249 9 Langa KM , Levine DA . The diagnosis and management of mild cognitive impairment: A clinical review. JAMA—Journal of the American Medical Association. American Medical Association; 2014. pp. 2551–2561. doi: 10.1001/jama.2014.13806 25514304 10 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. 11 Daniel B , Agenagnew L , Workicho A , Abera M . Psychometric Properties of the Montreal Cognitive Assessment (MoCA) to Detect Major Neurocognitive Disorder Among Older People in Ethiopia: A Validation Study. Neuropsychiatr Dis Treat. 2022;18 : 1789–1798. doi: 10.2147/NDT.S377430 36035074 12 Julayanont P , Tangwongchai S , Hemrungrojn S , Tunvirachaisakul C , Phanthumchinda K , Hongsawat J , et al . The Montreal Cognitive Assessment-Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low-Educated Elderly Adults. J Am Geriatr Soc. 2015;63 : 2550–2554. doi: 10.1111/jgs.13820 26648041 13 Rosca EC , Albarqouni L , Simu M . Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders. Neuropsychol Rev. 2019;29 : 313–327. doi: 10.1007/s11065-019-09412-9 31440882 14 Gluhm S , Goldstein J , Brown D , van Liew C , Gilbert PE , Corey-Bloom J . Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington’s disease. Mov Disord. 2013;28 : 1744–7. doi: 10.1002/mds.25578 23798501 15 Zietemann V , Georgakis MK , Dondaine T , Müller C , Mendyk A-M , Kopczak A , et al . Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology. 2018;91 : e1838–e1850. doi: 10.1212/WNL.0000000000006506 30333158 16 Carson N , Leach L , Murphy KJ . A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry. 2018;33 : 379–388. doi: 10.1002/gps.4756 28731508 17 Yang C , Wang L , Hu H , Dong X , Wang Y , Yang F . Montreal Cognitive Assessment: Seeking a Single Cutoff Score May Not Be Optimal. Evid Based Complement Alternat Med. 2021;2021 : 9984419. doi: 10.1155/2021/9984419 34616484 18 Pugh EA , Kemp EC , van Dyck CH , Mecca AP , Sharp ES . Effects of Normative Adjustments to the Montreal Cognitive Assessment. The American Journal of Geriatric Psychiatry. 2018;26 : 1258–1267. doi: 10.1016/j.jagp.2018.09.009 30314940 19 Schiess N , Villabona-Rueda A , Cottier KE , Huether K , Chipeta J , Stins MF . Pathophysiology and neurologic sequelae of cerebral malaria. Malar J. 2020;19 : 266. doi: 10.1186/s12936-020-03336-z 32703204 20 Siewe Fodjo JN , Njamnshi WY , Ngarka L , Nfor LN , Ayuk C , Mundih NN , et al . Association Between Ov16 Seropositivity and Neurocognitive Performance Among Children in Rural Cameroon: a Pilot Study. J Pediatr Neuropsychol. 2021;7 : 192–202. doi: 10.1007/s40817-021-00111-z 34868828 21 Akinyemi RO , Owolabi MO , Ihara M , Damasceno A , Ogunniyi A , Dotchin C , et al . Stroke, cerebrovascular diseases and vascular cognitive impairment in Africa. Brain Res Bull. 2019;145 : 97–108. doi: 10.1016/j.brainresbull.2018.05.018 29807146 22 Akinyemi RO , Ovbiagele B , Adeniji OA , Sarfo FS , Abd-Allah F , Adoukonou T , et al . Stroke in Africa: profile, progress, prospects and priorities. Nat Rev Neurol. 2021;17 : 634–656. doi: 10.1038/s41582-021-00542-4 34526674 23 Kissani N , Liqali L , Hakimi K , Mugumbate J , Daniel GM , Ibrahim EAA , et al . Why does Africa have the lowest number of Neurologists and how to cover the Gap? J Neurol Sci. 2022;434 : 120119. doi: 10.1016/j.jns.2021.120119 34982975 24 Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34: 290–6. 25 Chang YJ , Golby AJ , Albers GW . Detection of carotid stenosis. From NASCET results to clinical practice. Stroke. 1995;26 : 1325–8. doi: 10.1161/01.str.26.8.1325 7631330 26 Baumgartner RW , Mattle HP , Schroth G . Assessment of >/ = 50% and <50% intracranial stenoses by transcranial color-coded duplex sonography. Stroke. 1999;30 : 87–92. doi: 10.1161/01.str.30.1.87 9880394 27 Purroy F , Sánchez E , Lecube A , Arqué G , Vicente-Pascual M , Mauri-Capdevila G , et al . Prevalence and Predictors of Cerebral Microangiopathy Determined by Pulsatility Index in an Asymptomatic Population From the ILERVAS Project. Front Neurol. 2021;12 . doi: 10.3389/fneur.2021.785640 34970215 28 Masika GM , Yu DSF , Li PWC . Accuracy of the Montreal Cognitive Assessment in Detecting Mild Cognitive Impairment and Dementia in the Rural African Population. Arch Clin Neuropsychol. 2021;36 : 371–380. doi: 10.1093/arclin/acz086 31942599 29 Robbins RN , Joska JA , Thomas KGF , Stein DJ , Linda T , Mellins CA , et al . Exploring the Utility of the Montreal Cognitive Assessment to Detect HIV-Associated Neurocognitive Disorder: The Challenge and Need for Culturally Valid Screening Tests in South Africa. Clin Neuropsychol. 2013;27 : 437–454. doi: 10.1080/13854046.2012.759627 23336183 30 Kehoua G , Dubreuil C-M , Ndamba-Bandzouzi B , Guerchet M , Mbelesso P , Dartigues J-F , et al . People with Dementia in Sub-Saharan Africa: From Support to Abuse by Caregivers: Results of EPIDEMCA-FU Program in Congo. Dement Geriatr Cogn Dis Extra. 2019;9 : 163–175. doi: 10.1159/000489846 31097954 31 Toufic N. [Loaiasis and its ocular impact in Central Africa]. Bull Soc Ophtalmol Fr. 1985;85 : 1175–80.3870432 32 Fobi G , Gardon J , Santiago M , Ngangue D , Gardon-Wendel N , Boussinesq M . Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiol. 2000;7 : 27–39. 10652169 33 Van Bogaert L , Dubois A , Janssens PG , Radermecker J , Tverdy G , Wanson M . Encephalitis in loa-loa filariasis. J Neurol Neurosurg Psychiatry. 1955;18 : 103–19. doi: 10.1136/jnnp.18.2.103 14381919 34 Wanji S , Eyong EEJ , Tendongfor N , Ngwa CJ , Esuka EN , Kengne-Ouafo AJ , et al . Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment. PLoS Negl Trop Dis. 2017;11 . doi: 10.1371/journal.pntd.0005576 28686693 35 Kamgno J , Boussinesq M , Labrousse F , Nkegoum B , Thylefors BI , Mackenzie CD . Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg. 2008;78 : 546–51. 18385346 36 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9 : 689–701. doi: 10.1016/S1474-4422(10)70104-6 20610345 37 Same Ekobo A , Same-Voisin C , Eben-Moussi E , Ongmagne MJ . A propos d’un cas de méningo-encéphalite filarienne à Loa loa. Rappels des critères de diagnostic de certitude. Afr Med. 1981;20 : 359–361. 38 Cauchie C , Rutsaert J , Thys O , Bonnyns M , Perier O . [Encephalitis due to Loa-Loa, treated with the combination of cortisone and carbamazine]. Rev Belg Pathol Med Exp. 1965;31 : 232–244.5837048 39 Kivits M. [Four cases of fatal encephalitis with invasion of the cerebrospinal fluid by Microfilaria loa]. Ann Soc Belg Med Trop. 1952;32 : 235–242. 40 Arrey-Agbor DB , Nana-Djeunga HC , Mogoung-Wafo AE , Mafo M , Danwe C , Kamgno J . Case report: Probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of Loa loa microfilariaemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg. 2018;99 : 112–115. doi: 10.4269/ajtmh.17-0664 29741149 41 Chesnais CB , Nana-Djeunga HC , Njamnshi AK , Lenou-Nanga CG , Boullé C , Bissek ACZK , et al . The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. Lancet Infect Dis. 2018;18 : 1278–1286. doi: 10.1016/S1473-3099(18)30425-0 30268645 42 Sakti H , Nokes C , Subagio Hertanto W , Hendratno S , Hall A , P Bundy DA . Evidence for an association between hookworm infection and cognitive function in Indonesian school children. 1999. 43 Jardim-Botelho A , Raff S , De Ávila Rodrigues R , Hoffman HJ , Diemert DJ , Corrêa-Oliveira R , et al . Hookworm, Ascaris lumbricoides infection and polyparasitism associated with poor cognitive performance in Brazilian schoolchildren. Tropical Medicine and International Health. 2008;13 : 994–1004. doi: 10.1111/j.1365-3156.2008.02103.x 18627581 44 Pabalan N , Singian E , Tabangay L , Jarjanazi H , Boivin MJ , Ezeamama AE . Soil-transmitted helminth infection, loss of education and cognitive impairment in school-aged children: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12 . doi: 10.1371/journal.pntd.0005523 29329288